Skip to main content
ANAVEX LIFE SCIENCES CORP. logo

ANAVEX LIFE SCIENCES CORP. — Investor Relations & Filings

Ticker · AVXL ISIN · US0327973006 LEI · 549300K1I5L8COCQ8W36 US Manufacturing
Filings indexed 577 across all filing types
Latest filing 2018-03-05 Director's Dealing
Country US United States of America
Listing US AVXL

About ANAVEX LIFE SCIENCES CORP.

https://www.anavex.com

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for central nervous system (CNS) disorders. The company develops targeted drug candidates for neurodegenerative and neurodevelopmental diseases, including Alzheimer's disease, Parkinson's disease, and Rett syndrome. Anavex's approach is centered on precision medicine, utilizing small molecule drugs designed to restore cellular homeostasis. Its lead investigational compound, blarcamesine (ANAVEX®2-73), is an orally available sigma-1 receptor (S1R) agonist being evaluated for its potential to treat a range of neurological conditions.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2018-03-05 English
AMENDMENT NO. 1
Major Shareholding Notification
2018-02-14 English
10-Q
Interim / Quarterly Report Q1 2018
2018-02-07 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-12-15 English
4
Director's Dealing
2017-12-15 English
10-K
Annual Report FY 2017
2017-12-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.